ReviewJACC. Asia2022
Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia.
Review in JACC. Asia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety and efficacy of exercise training in patients with pulmonary hypertension: a systematic review and meta-analysis.European journal of applied physiology · 2026Pooled it
- Germline and somatic variants in DNMT3A and other clonal haematopoiesis of indeterminate potential genes contribute to pulmonary arterial hypertension.European heart journal · 2026Article
- Pilot study to validate endothelium collection from pulmonary artery balloon catheter in children.Pediatric research · 2026Article
- Uric Acid-to-Albumin Ratio as a Complementary Biomarker for In-Hospital Risk Stratification in Patients with Pulmonary Hypertension: A Retrospective Cohort Study.Journal of cardiovascular development and disease · 2026Article
- Global Burden of Pediatric Pulmonary Arterial Hypertension, 1990-2021: A Systematic Analysis from the Global Burden of Disease Study 2021.Pediatric cardiology · 2026Article
- Challenges and Strategies in Managing Pulmonary Arterial Hypertension Within the Indian Healthcare System: A Consensus Statement From the Pulmonary Vascular Research Institute India Taskforce.Pulmonary circulation · 2026Article
- Development of a Noninvasive Prediction Score for Post-Capillary Pulmonary Hypertension in a Multi-Ethnic Asian Population.JACC. Asia · 2026Article
- Conceptual Reconsideration of the Classification of Pulmonary Hypertension: From 5 Groups to 2 Groups.JACC. Asia · 2026Review
- The New Era of Pulmonary Hypertension: The Dawn of Disease Modification & Therapeutic Modalities.Journal of cardiovascular development and disease · 2026Review
- Pulmonary Arterial Hypertension and Cancer: Unveiling Parallels in Epidemiology, Clinical Pathways, and Therapeutic Strategies.Journal of market access & health policy · 2026Article
- Mechanisms Underlying Altitude-Induced and Group 3 Pulmonary Hypertension.International journal of molecular sciences · 2026Review
- Transformative Approaches to Biomarker Assessment and Clinical Profiles in Pulmonary Hypertension Patients : Short title: Biomarker Assessment and Clinical Profiles in Pulmonary Hypertension Patients.Galen medical journal · 2026Review
- Impact of Seropositivity on Mortality and Extra-Articular Manifestations in Rheumatoid Arthritis: A Nationwide Propensity-Matched Cohort Study.Mediterranean journal of rheumatology · 2025Article
- Macrophage plasticity and glucose metabolism: the role of immunometabolism in pulmonary arterial hypertension.Clinical science (London, England : 1979) · 2025Review
- Global, Regional, and National Burden of Pulmonary Arterial Hypertension from 1990 to 2021 and Projections to 2040: A Systematic Analysis of Incidence, Mortality, and Disability-Adjusted Life Years.Current medical science · 2025Article
- Pulmonary pressure increases during acute exacerbation in COPD and clinical outcome.The European respiratory journal · 2025Article
- Therapeutic targets for pulmonary arterial hypertension: insights into the emerging landscape.Expert opinion on therapeutic targets · 2025Review
- Physician perspectives on pulmonary hypertension in ILD: results of a cases-based survey.BMC pulmonary medicine · 2025Article
- Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact for Clinical Use (SYMPACT-CP): a qualitative interview study.BMC pulmonary medicine · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) is caused by a range of conditions and is important to recognize as it is associated with increased mortality. Pulmonary arterial hypertension refers to a group of PH subtypes affecting the distal pulmonary arteries for which effective treatment is available. The hemodynamic definition of pulmonary arterial hypertension has recently changed which may lead to greater case recognition and earlier treatment. The prevalence of specific PH etiologies may differ depending on geographic region. PH caused by left heart disease is the most common cause of PH worldwide. In Asia, there is greater proportion of congenital heart disease- and connective tissue disease- (especially systemic lupus erythematosus) related PH relative to the West. This review summarizes the definition, classification, and epidemiology of PH as it pertains to Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.